{
    "title": "Novavax raises doubts about its ability to remain in business",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11804611/Novavax-raises-doubts-ability-remain-business.html",
    "date": "2023-02-28",
    "keywords": [
        "company",
        "vaccine",
        "jacobs",
        "year",
        "novavax",
        "fall",
        "value",
        "spending",
        "government",
        "cash",
        "share",
        "operating",
        "plan",
        "end",
        "ceo",
        "job",
        "shot",
        "market",
        "york",
        "feb",
        "maker",
        "inc",
        "tuesday",
        "ability",
        "business",
        "vaccination",
        "campaign",
        "uncertainty",
        "revenue",
        "arbitration",
        "alliance",
        "gavi",
        "flow",
        "forecast",
        "capital",
        "quarter",
        "position",
        "executive",
        "john",
        "january",
        "interview",
        "hand",
        "term",
        "fact",
        "messenger",
        "food",
        "drug",
        "administration",
        "strain",
        "selection",
        "fda",
        "health",
        "standpoint",
        "sooner",
        "clarity",
        "path",
        "rate",
        "process",
        "footprint",
        "supply",
        "chain",
        "portfolio",
        "structure",
        "infrastructure",
        "target",
        "technology",
        "pipeline",
        "product",
        "rollout",
        "uptake",
        "trading",
        "worth",
        "july",
        "advantage",
        "shift",
        "pfizerbiontech",
        "moderna",
        "option",
        "reporting",
        "erman",
        "humer",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}